Localization of class i histocompatibility molecule assembly by subfractionation of the early secretory pathway

Class I molecules of the major histocompatibility complex bind peptides derived from cytosolic proteins and display them on the cell surface. This function alerts cytotoxic T cells to the presence of intracellular pathogens. Class I molecule assembly requires the association of the heavy chain with β₂-microglobulin, accompanied by peptide loading via specific transporters. This study localizes where these assembly steps take place, using monoclonal antibodies recognizing class I molecules in different assembly states to analyze subcellular fractions of the early secretory pathway. The distribution of peptide-loaded class I molecules was more localized than the distribution of the total pool of class I molecules in the early secretory pathway. Loaded molecules colocalized with the peptide transporter, free heavy chains, and the chaperone calnexin in high density rough endoplasmic reticulum (RER) membranes. These data suggest that subunit assembly and peptide acquisition occur at the same intracellular site. Class I molecules also localized to less dense subfractions of the early secretory pathway, which contained comparatively less peptide-loaded molecules than the high density RER fractions, at steady state. Following a 15 °C temperature block, class I molecules accumulated in these less dense membrane fractions, indicating that these fractions represent the intermediate compartment where empty class I molecules are trapped in mutant cells. In the presence of cycloheximide, a pool of class I molecules recycling to the RER was detected, suggesting empty molecules recycle to acquire peptide.     

抗人大肠癌单链抗体的构建、表达及其体内外生物学活性的检测

目的 将抗人大肠癌单克隆抗体ND-1(mAb)的VR和VL基因进行重组，构建和表达ND－1scFv，并对其在体内外的生物学活性进行检测。采用RT－PCR技术，从能够分泌mAb ND-1的鼠杂交瘤细胞中扩增VH和RL基因，通过重叠延伸拼接PCR在VH和VL基因间引入连接短肽，体外构构建ND－1scFv基因，并在大肠杆菌中表达。采用间接免疫荧光（IFA）EY IF工IMPG-1scFv的免疫学活性。用^99Tc^m标记ND－1scFv后，将偶联物给予荷瘤裸鼠，观察其在动物体内的显像及生物学分布。结果 SDS－PAGEW显示，重组蛋白Mr为30000，同预期结果一致。IFA及ELISA检测表明，ND－1scFv保留了与亲本抗体相近的免疫学活性，对表达相应抗原的靶细胞具有行异结合活性。体内放射免疫实验显示，^99Tc^m-ND-1scFv在荷瘤小鼠体内的生物学分布，呈明显的肿瘤积聚趋向，注入体内1h血中T／NT即在2．61。结论 获得免疫学活性良好的ND－1scFv，对荷瘤动物体内肿瘤的定位快速，准确，可望成为有效的肿瘤诊断和治疗的导向载体。     

Morphine-6beta-glucuronide modulates the expression of inducible nitric oxide synthase

The immunomodulatory effects of morphine are well established; however, suprisingly little is known about the immunomodulatory properties of the major metabolites of morphine. The present study tests the hypothesis that expression of inducible nitric oxide synthase (iNOS) is modulated by the administration of the morphine metabolite, morphine-6-glucuronide. The initial study using rats shows that morphine-6-glucuronide administration (0, 1.0, 3.163, 10 mg/kg s.c.) results in a pronounced reduction in lipopolysaccharide (LPS)-induced expression of iNOS (inducible nitricoxide synthease) in spleen, lung, and liver tissue as measured by western blotting. Morphine-6-glucuronide also produces a reduction in the level of plasma nitrite/nitrate, the more stable end-product of nitric oxide degradation. In a subsequent study, administration of the opioid receptor antagonist, naltrexone (0.1 mg/kg) prior to the injection of morphine-6-glucuronide (10 mg/kg) blocks the morphine-6-glucuronide induced reduction of iNOS expression and plasma nitrite/nitrite levels indicating that the effect is mediated via the opioid-receptor. This study provides the first evidence that morphine-6-glucuronide alters the expression of iNOS.     

IPFM，MIPFM模型产生的仿真心率变异性信号的周期图与AR谱分析研究

为了研究不同心电序列转换方式及不同谱估计方法对心率变异性（ＨＲＶ）信号谱分析结果的影响，本文对积分脉冲频率调制（ＩＰＦＭ）模型及修正积分脉冲频率调制（ＭＩＰＦＭ）模型在输入不同振幅与频率的正弦信号时所产生的随机点过程，用两种心电序列转换方法进行转换得到仿真ＨＲＶ信导；然后，采用周期图与自回归（ＡＲ）谱估计方法计算这种厉真ＨＲＶ信号的功率谱。研究结果表明：①对于ＭＩＰＦＭ模型产生的随机点过程，同一心电序列转换方法所得出的仿真ＨＲＶ信号的ＡＲ谱与周期图的谱峰功率估计基本一致；而对ＩＰＦＭ模型则不完全一致。②ＭＩＰＦＭ模型仿真实验表明，对实际ＨＲＶ信号谱分析，使用低，高频谱峰功率比（ＲＦ）作为反映心脏自主神经张力平衡的指标时，除心电序列传换及谱估计方法可能造成的误差外，当低频谱峰靠近极低频谱峰时，根据ＲＦ值解释生理实验结果会有校大误差。③座分析实际ＨＲＶ信号的工作中，不同心电序列转换方式产生的伪谐波对ＨＲＶ谱分析结果的影响不大。     

Expression of transforming growth factor alpha in human tissues: Immunohistochemical study and Northern blot analysis

Summary The expression of transforming growth factor alpha (TGF-) was examined in various human tissues and the fetus, using immunohistochemistry and Northern blot analysis. TGF- immunoreactivity was detected mainly in the epithelial cells of the digestive tract, liver, pancreas, kidney, thyroid, adrenal, skin, mammary gland and genital organs. In the digestive tract, epithelial cells with regenerative change or hyperplastic change showed strong immunoreactivity to TGF-. Peripheral nerve, vessels, megakaryocytes and macrophages in the lung and spleen were also positive for TGF-. By Northern blot analysis the expression of TGF- mRNA was confirmed in the digestive tract, salivary gland, thyroid, kidney and mammary gland. In the human fetus, the nerve tissues, liver, adrenal and kidney were positive for TGF-. Strong immunoreactivity to TGF- was observed in the hepatocytes of the fetus. These findings indicate that TGF- is produced by a variety of nonneoplastic cells in both adult and fetal tissues.     

Anti-arthritic properties of FK506 on collagen-induced arthritis in rats

Objective and design:To determine the effect of FK506 (tacrolimus) on paw inflammation, TNF- expression in joint, and bone and cartilage destruction in type II collagen-induced arthritis (CIA) model in rats.Methods:CIA was induced by immunization of female Lewis rats with an emulsion of bovine type II collagen and incomplete Freunds adjuvant. Paw inflammation was assessed by the increase in paw volume. Tumor necrosis factor (TNF) - expression in hind knee joint was assessed by immunohistochemical analysis. Lesions of bone and cartilage were assessed on the basis of histological change in knee joint, radiographic analysis in hind paw, bone mineral density in femora and proteoglycan contents in the cartilage of femoral heads. FK506 at doses of 1, 1.8 and 3.2 mg/kg or its placebo formulation was orally administered to rats for 28 days from the day after immunization (n = 10). Effect of FK506 was compared with that of vehicle (distilled water).Results:FK506 at a dose of 1.8 mg/kg significantly suppressed paw swelling (p < 0.01) and histological change in knee joint (p < 0.05). Tumor necrosis factor (TNF)- was mainly expressed in the region with a marked infiltration of inflammatory cells in the hind knee joint. FK506 (3.2 mg/kg) markedly reduced TNF- expression. FK506 at a dose of 1.8 mg/kg suppressed radiographic changes in hind paw (p < 0.05) and also recovered the decrease in bone mineral density in the femora (p < 0.05). Proteoglycan contents in the cartilage of femoral heads were determined to evaluate the cartilage destruction more quantitatively and found to significantly decrease in CIA rats. FK506 at a dose of 1.8 mg/kg recovered the loss of proteoglycan contents (p < 0.01).Conclusion:These results show that FK506 is effective in suppressing inflammation, TNF- expression in joint, and damage to bone and cartilage in rat CIA, and may be useful in the treatment of rheumatoid arthritis.     

脑益嗪对实验性血栓形成的影响

脑益嗪是—钙拮抗剂。本实验用颈动—静脉血流旁路术和改良的chandler氏体外血栓法研宄了脑益嗪的抗血栓作用。结果表明:脑益嗪对两种方法形成的血栓均有明显的抑制作用,二种方法的结果基本一致。因此,本文提示脑益嗪除直接扩张血管外,尚有很强的抗血栓作用,其效价强度优于阿斯匹林。     

Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy

BACKGROUND: We recently described patients with soybean allergy mainly mediated by cross-reactivity to birch pollen allergens. A majority of those patients were reported to have peanut allergy. OBJECTIVE: We sought to study the occurrence of peanut allergy in patients allergic to birch pollen and characterized the Bet v 1-homologous peanut allergen Ara h 8. METHODS: Recombinant Ara h 8 was cloned with degenerated primers and expressed in Escherichia coli. Nine Swiss and 11 Dutch patients with peanut and birch pollen allergy and a positive double-blind, placebo-controlled food challenge result to peanut were investigated for IgE reactivity to birch pollen and purified peanut allergens and cross-reactivity between birch and peanut. Ara h 8 stability against digestion and roasting was assessed by means of RAST inhibition. The IgE cross-linking potency of Ara h 8 was tested on the basis of basophil histamine release. RESULTS: During double-blind, placebo-controlled food challenge, all patients experienced symptoms in the oral cavity, progressing to more severe symptoms in 40% of patients. CAP-FEIA detected recombinant (r) Ara h 8-specific IgE in 85%. IgE binding to Ara h 8 was inhibited by Bet v 1 in peanut extract immunoblotting and in RAST inhibition. In EAST inhibition recombinant rAra h 8 inhibited IgE binding to peanut in 4 of 7 tested patient sera. Antipeanut response was dominated by Ara h 8 in 12 of 17 tested patients. Furthermore, our results demonstrate a low stability of Ara h 8 to roasting and no stability to gastric digestion. Basophil histamine release with rAra h 8 was more than 20% in 5 of 7 tested sera. CONCLUSIONS: Peanut allergy might be mediated in a subgroup of our patients by means of cross-reaction of Bet v 1 with the homologous peanut allergen Ara h 8.